We are at the beginning of a new age in cancer therapy. With
a large and growing number of patents and applications in
this space, we can expect a large amount of patent litigation
in the years to come as companies look to safeguard their
market share. Frances Salisbury and Adam Gregory of
Mewburn Ellis LLP look into the recent FDA approvals, an
important landmark in cellular immunotherapy.